Agomab Therapeutics NV

Agomab Therapeutics NV (NASDAQ:AGMB) is a publicly traded company in the Life Sciences sector. Wiseek monitors AGMB SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

• Agomab Secures Cash Runway to 2029 with $208M IPO, Confirms Key Clinical Milestones for H2 2026 (2026-04-23)
• Agomab Therapeutics Advances Two Lead Candidates to Phase 2, Extends Cash Runway to H1 2029 (2026-04-23)
• Agomab Secures U.S. Patent for Key IPF Drug AGMB-447, Protecting IP Through 2041 (2026-03-26)
• Agomab Therapeutics Amends Articles, Authorizes Massive Capital Increase (2026-03-05)
• Institutional Investor LSP 7 Discloses 10.6% Stake in Agomab Therapeutics Post-IPO (2026-02-17)

Insider Transactions

AGMB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.